GL1X · GenesisL1 explorer

Research workbench

Human ERK2 in complex with an irreversible inhibitor

Analyse Human ERK2 in complex with an irreversible inhibitor in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
4ZZM
Type
protein
Length
345 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Mitogen-activated protein kinase 1
EC
2.7.11.24
UniProt
P28482
Ligands
CQ6, SO4
Pockets
3 · best druggability 0.66

Structure

x-ray diffraction · 1 distinct chain · 40% helix, 15% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AMitogen-activated protein kinase 1 (EC 2.7.11.24)protein34540% helix, 15% strandP28482

Ligands and binding sites

  • CQ6 · 7-ethylsulfonyl-N-(oxan-4-yl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-2-amine · ligand · chains A
  • SO4 · Sulfate ion · ion · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

3 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
14210.660.7938CQ6
2700.540.8614empty
31320.490.7927empty

Modifications

Observed in the structure: 1 covalent, 1 modified (covalent ligand, artifact).

Compared structures

  • 4ZZM · Human ERK2 in complex with an irreversible inhibitor · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.